On March 4, Novartis published a clinical trial of a Phase III study of Cosentyx in the treatment of moderate to severe plaque psoriasis at the 2019 Annual Meeting of the American Academy of Dermatology (AAD2019). The reason for this study is that 441 of the 543 patients with… Continue Reading The third phase of clinical data of Cosynmyx China, a new psoriasis drug, was released for the first time: excellent efficacy and significant benefit

  On December 12, Janssen announced the 48-week results of the head-to-head PKECLIPSE Phase III study of Tremfya (guselkumab) and Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis. In the Tremfya treatment group, the psoriasis area and severity index improved by more than 90% (PASI 90, primary… Continue Reading Johnson & Johnson’s new psoriasis PK wins, Novartis Cosentyx is counterattacked

Evaluate Pharma’s report “World Preview 2018, Outlook to 2024” published in BIO2018 recently pointed out that Novartis will surpass Pfizer and Roche in 2024 and become the world’s largest prescription drug company with a revenue of 53.2 billion U.S. dollars.   Global Prescription Drug Corporation TOP10 in 2024 Analysts pointed… Continue Reading In 2024, Novartis will become the world’s largest pharmaceutical company?